Healthcare [ 13/13 ] | Diagnostics & Research [ 77/164 ]
NASDAQ | Common Stock
Centogene N.V., together with its subsidiaries, engages in the research and development of products for human genetics in Europe, the Middle East, North America, Latin America, and the Asia Pacific.
It provides data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases.
It operates through two segments: Pharmaceutical and Diagnostics.
The company provides target and drug screening, clinical development, market access and expansion, as well as CENTOGENE Biodatabank licenses and insight report services.
In addition, it offers various services, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors.
The company has a collaboration with Evotec SE.
Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Dec 21, 23 | -0.45 Decreased by -18.47% | -0.39 Decreased by -15.58% |
| Sep 7, 23 | -0.41 Increased by +15.58% | -0.37 Decreased by -10.05% |
| May 16, 23 | -0.09 Increased by +67.86% | -0.37 Increased by +75.68% |
| Dec 31, 22 | -0.10 Increased by +80.39% | -0.41 Increased by +75.61% |
| Dec 22, 22 | -0.38 Increased by +60.42% | -0.39 Increased by +2.56% |
| Jul 15, 22 | -0.48 Decreased by -29.73% | -0.50 Increased by +4.00% |
| Jun 29, 22 | -0.28 Decreased by -255.56% | -0.53 Increased by +47.17% |
| Mar 31, 22 | -0.51 Decreased by -55.02% | -0.63 Increased by +19.05% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 12.31 M Increased by +9.95% | -12.23 M Decreased by -2.87% | Decreased by -99.32% Increased by +6.44% |
| Mar 31, 23 | 13.04 M Increased by +26.29% | -7.82 M Decreased by -20.60% | Decreased by -59.94% Increased by +4.50% |
| Dec 31, 22 | N/A Decreased by -100.00% | N/A Increased by +100.00% | - - |
| Sep 30, 22 | 13.04 M Decreased by -56.81% | -7.82 M Increased by +63.88% | Decreased by -59.94% Increased by +16.38% |
| Jun 30, 22 | 11.20 M Decreased by -78.41% | -11.89 M Decreased by -48.22% | Decreased by -106.15% Decreased by -586.57% |
| Mar 31, 22 | 10.33 M Decreased by -85.30% | -6.48 M Decreased by -293.03% | Decreased by -62.77% Decreased by -1.41 K% |
| Dec 31, 21 | 42.90 M Decreased by -38.94% | -12.30 M Decreased by -466.26% | Decreased by -28.67% Decreased by -699.83% |
| Sep 30, 21 | 30.20 M Decreased by -16.83% | -21.64 M Decreased by -283.76% | Decreased by -71.68% Decreased by -361.40% |